Cite
Findings from University of Illinois in the Area of Solid Cancer Described [Phase I Study of Aurora a Kinase Inhibitor Alisertib (Mln8237) In Combination With Selective Vegfr Inhibitor Pazopanib for Therapy of Advanced Solid Tumors]
MLA
“Findings from University of Illinois in the Area of Solid Cancer Described [Phase I Study of Aurora a Kinase Inhibitor Alisertib (Mln8237) In Combination With Selective Vegfr Inhibitor Pazopanib for Therapy of Advanced Solid Tumors].” Obesity, Fitness & Wellness Week, Sept. 2019, p. 778. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.598750420&authtype=sso&custid=ns315887.
APA
Findings from University of Illinois in the Area of Solid Cancer Described [Phase I Study of Aurora a Kinase Inhibitor Alisertib (Mln8237) In Combination With Selective Vegfr Inhibitor Pazopanib for Therapy of Advanced Solid Tumors]. (2019, September 14). Obesity, Fitness & Wellness Week, 778.
Chicago
Obesity, Fitness & Wellness Week. 2019. “Findings from University of Illinois in the Area of Solid Cancer Described [Phase I Study of Aurora a Kinase Inhibitor Alisertib (Mln8237) In Combination With Selective Vegfr Inhibitor Pazopanib for Therapy of Advanced Solid Tumors],” September 14. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.598750420&authtype=sso&custid=ns315887.